

1 **Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The**  
2 **Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study**

3 **Authors**

4 Bolarinde J. Lawal<sup>1+</sup> & Katherine E Gallagher<sup>2,3+\*</sup>, Jonathan Kitonsa<sup>4</sup>, Daniel Tindanbil<sup>1</sup>,  
5 Kambale Kasonia<sup>5</sup>, Abdoulie Drammeh<sup>1</sup>, Brett Lowe<sup>2</sup>, Daniel Mukadi-Bamuleka<sup>6</sup>, Catriona  
6 Patterson<sup>2</sup>, Brian Greenwood<sup>2</sup>, Mohamed Samai<sup>7</sup>, Bailah Leigh<sup>7</sup>, Kevin K. A. Tetteh<sup>2</sup>, Eugene  
7 Ruzagira<sup>4&</sup> & Deborah Watson-Jones<sup>2,10&</sup> & Hugo Kavunga-Membo<sup>6&</sup>

8 + These authors contributed equally

9 & The authors contributed equally

10 \*Corresponding author: [Katherine.gallagher@lshtm.ac.uk](mailto:Katherine.gallagher@lshtm.ac.uk)

11 Affiliations:

12 <sup>1</sup> LSHTM-COMAHS Research Partnership, Kambia District, Sierra Leone

13 <sup>2</sup> London School of Hygiene & Tropical Medicine (LSHTM), London, WC1E 7HT, United  
14 Kingdom

15 <sup>3</sup> KEMRI-Wellcome Trust Research Programme, PO-Box 230 80108, Kilifi, Kenya

16 <sup>4</sup> MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda

17 <sup>5</sup> LSHTM-INRB Research Partnership, Goma, Democratic Republic of the Congo

18 <sup>6</sup> Laboratoire Rodolphe Merieux-Institute National Research biomedical (INRB), Goma,  
19 Democratic Republic of the Congo

20 <sup>7</sup> University of Sierra Leone College of Medicine and Allied Health Sciences (COMAHS),

21 Freetown, Sierra Leone

22 <sup>10</sup> Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza,

23 Tanzania

24 **Abstract (197/200)**

25 Objectives

26 We assessed the prevalence of immunoglobulin G (IgG) and immunoglobulin M (IgM)  
27 against four endemic human coronaviruses (HCoVs) and two SARS-CoV-2 antigens, among  
28 vaccinated and unvaccinated staff at health care centres in Uganda, Sierra Leone, and the  
29 Democratic Republic of Congo (DRC).

30 Methods

31 Government health facility staff who had patient contact in Goma (DRC), Kambia District  
32 (Sierra Leone), and Masaka District (Uganda) were enrolled. Questionnaires and blood  
33 samples were collected at three timepoints over four months. Blood samples were analysed  
34 with the Luminex MAGPIX®.

35 Results

36 Among unvaccinated participants, the prevalence of IgG/IgM antibodies against SARS-CoV-2  
37 RBD or N-protein at enrolment was 70% in Goma (138/196), 89% in Kambia (112/126) and  
38 89% in Masaka (190/213). IgG responses against endemic HCoVs at baseline were not  
39 associated with SAR-CoV-2 sero-acquisition during follow-up. Among vaccinated  
40 participants, those who had evidence of SARS-CoV-2 IgG/IgM at baseline tended to have  
41 higher IgG responses to vaccination compared to those SARS-CoV-2 seronegative at  
42 baseline, controlling for the time of sample collection since vaccination.

43 Conclusions

44 The high levels of natural immunity and hybrid immunity should be incorporated into both  
45 vaccination policy and prediction models of the impact of subsequent waves of infection in  
46 these settings.

47

48 **Keywords:** seroprevalence, hybrid immunity, cross-reactivity, SARS-CoV-2, human  
49 coronaviruses

50

51 **Word count:** 3499/ 3500

## 52 Introduction

53 Natural immunity and ‘hybrid immunity’, generated after a mixture of both natural infection  
54 and vaccination, could illicit more effective and longer-lasting protection against subsequent  
55 symptomatic infection with SARS-CoV-2, than vaccination alone [1, 2]. Vaccine coverage  
56 with at least one dose of a prophylactic COVID vaccine was 4.6% in the Democratic Republic  
57 of the Congo (DRC), 34.1% in Sierra Leone, and 40.5% in Uganda in August 2022[3]. The  
58 outcome of future waves of SARS-CoV-2 infection will be determined by both natural and  
59 hybrid immunity and whether other common circulating pathogens like endemic human  
60 coronaviruses (HCoVs) produce a non-specific protective response.

61 Prior to SARS-CoV-2, the most common human coronaviruses (HCoVs) were the alpha-  
62 HCoVs (OC43, HKU1), and the beta-HCoVs (NL63 and 229E), which cause mild to moderate  
63 respiratory tract diseases. Globally, most people acquire one or more of these viruses in  
64 their lifetime, and develop symptoms such as cough, sore throat, runny nose, fever,  
65 headache, and general malaise [4-6]. In pre-pandemic samples, OC43 and HKU1 anti-spike  
66 (anti-S) antibodies have displayed cross-binding to the SARS-CoV-2 Spike protein (S-Protein)  
67 with some neutralising activity[7, 8], although it is still unclear whether prior exposure to  
68 HCoVs provides any protection against SARS-CoV-2 infection [9, 10]. Additionally, both  
69 vaccination and natural infection with SARS-CoV-2 have been shown to generate IgG which  
70 binds S-proteins from other beta-HCoVs (HKU1 and OC43; but not alpha-HCoVs NL63 or  
71 229E) [7, 9, 11, 12]. SARS-CoV-2 infection and/or vaccination may stimulate memory  
72 responses and generate production of IgG to HCoVs in adults with prior exposure to HCoVs  
73 or there may simply be cross-binding to common epitopes. Results differ on whether these  
74 anamnestic responses are protective against infection with SARS-CoV-2. Pre-existing IgG

75 antibodies to the nucleocapsid protein (N-protein) of HCoV 229E were weakly correlated  
76 with remaining uninfected with SARs-CoV-2 infection in a cohort of health care workers  
77 (HCWs) but were not correlated with protection from infection in a large retrospective  
78 analysis of stored samples and electronic health records[13]. However, both studies found  
79 that pre-existing IgG antibodies to HCoVs correlated with less severe symptoms in those  
80 who did become SARS-CoV-2 positive[13, 14]. It may be important to account for levels of  
81 prior exposure to other HCoVs when estimating natural immunity to SARS-CoV-2 and to  
82 control for the presence of cross-reactive antibodies to HCoVs when using seroprevalence  
83 to SARS-CoV-2 as a marker of exposure to the virus[7, 8].

84 We aimed to assess the prevalence of IgG and IgM to two SARs-CoV-2 antigens, the  
85 nucleocapsid protein (NP), a marker of natural exposure, and the receptor-binding domain  
86 (RBD) of the spike protein which could be a marker of natural exposure or vaccine-induced  
87 immunity, among vaccinated and unvaccinated staff at health care centres in Uganda, Sierra  
88 Leone, and the DRC. We assessed IgG and IgM responses to four endemic HCoVs and  
89 explored whether these correlated with a reduced risk of acquisition of SARS-CoV-2 during  
90 the study or affected the immune responses to subsequent vaccination. We hypothesised  
91 that there may be different rates of sero-acquisition across the different settings that may  
92 be correlated with differences in HCoV seroprevalence or other risk factors.

## 93 **Methods**

### 94 ***Study Design***

95 This was a longitudinal observational study of SARS-CoV-2 serology among staff working  
96 within primary healthcare facilities. Blood samples were collected over four months at three

97 timepoints between February-June 2021 in DRC, March-July 2021 in Sierra Leone and July-  
98 November 2021 in Uganda.

### 99 ***Study Setting and Population***

100 The study took place in the city of Goma, DRC, and both urban and rural locations in Kambia  
101 District, Sierra Leone, and Masaka District in Uganda. A list of all government health facilities  
102 in each area was compiled. In Masaka District, all 25 government health centres were  
103 selected. In Goma, all 21 urban and accessible health centres were selected. In Kambia  
104 District, a random number generator was used to select 29 health facilities, proportional to  
105 the total number of health posts and health centres in the district.

106 Sierra Leone reported its first COVID-19 case on 31 March 2020 [15], the DRC on 10 March  
107 2020 [16], and Uganda on 21 March 2020 [17]. COVID-19 vaccination was launched in Sierra  
108 Leone on 15 March 2021 [18], in DRC on 19 April 2021 [19], and in Uganda on 10 March  
109 2021 [20, 21].

### 110 ***Sample Collection & processing***

111 We administered a short questionnaire to consenting staff at the selected health facilities to  
112 collect demographic data, information on comorbidities, vaccination status, reported  
113 symptoms of COVID-19 and contact with confirmed COVID-19 cases in their household,  
114 community or at work. At each site, a trained phlebotomist in appropriate Personal  
115 Protective Equipment (PPE), compliant with local guidelines, collected a 5ml venous blood  
116 sample into a Serum Sample Separator Tube. In each country, blood samples were allowed  
117 to clot upright and transported from the field to the local laboratories at 2-15°C. In the  
118 laboratory, serum was separated into aliquots and was frozen at -20°C. Each participant was

119 followed up at two further visits at two-month intervals. At each visit, updated information  
120 on his/her COVID-19 vaccination status and contact data were recorded and a blood sample  
121 was collected. One aliquot of serum from each visit from DRC and Uganda was shipped at -  
122 80°C to the research laboratory in Kambia town, Sierra Leone.

123 All samples from all participants were run on the Luminex MAGPIX® platform (Luminex,  
124 Texas) to test for IgG and IgM antibodies to SARS-CoV-2 NP and RBD, OC43 NP, 229E NP,  
125 HKU1 NP, NL63 S1 and MERS NP by adapting a previously established assay [22] (Patterson  
126 et al., 2022 [Manuscript in preparation]). The IgG assay achieved sensitivity and specificity of  
127 98.8% and 97.9% for RBD, respectively, and 95.3% and 99.0% for NP, respectively. The IgM  
128 assay achieved sensitivities and specificities of 95.6% and 100% for RBD, respectively, and  
129 65.8% and 100% for NP, respectively. (Patterson et al., 2022 [Manuscript in preparation]).  
130 The results of the multiplex assay were reported in units of Mean Fluorescent Intensity  
131 (MFI) and were defined as seropositive if they were 3 standard deviations above the mean  
132 MFI of 40 European pre-pandemic negative controls provided by Public Health England  
133 (Public Health England, 2016). Positive SARS-COV-2 control pools were from NIBSC and were  
134 used as plate controls (20/B770; 20/130).

### 135 ***Statistical Analysis***

136 Seroprevalence to SARS-CoV-2 was defined if a sample was seropositive for IgG or IgM to  
137 either the SARS-CoV-2 RBD or the NP and was tabulated stratified by vaccination status.  
138 Seroprevalence to other endemic HCoVs was not possible to define given the lack of true  
139 negative controls. In sensitivity analyses of SARS-CoV-2 seroprevalence, we excluded  
140 samples with very high MFI to the endemic HCoVs, to check if SARS-CoV-2 seroprevalence  
141 estimates changed in this sub-set of samples. We defined these samples as those with MFI



142 units to endemic HCoVs that were three or more standard deviations above the MFI to that  
143 HCoV antigen in the SARS-CoV-2 negative control samples. The SARS-CoV-2 negative control  
144 samples were sera from European adults and likely included some who had a history of  
145 exposure to HCoVs but these represented the closest we had to an HCoV naïve population  
146 as HCoV infections are thought to be less prevalent in Europe than in Africa[23].

147 Correlations in IgG responses that could indicate cross-binding were assessed by plotting the  
148 MFI units of IgG to each antigen against one-another and calculating the Pearson's  
149 correlation coefficient.

150 Exploratory analyses examined factors associated with remaining IgG/M seronegative i.e.,  
151 not seroconverting to SARS-CoV-2 RBD/N-protein during follow-up, using logistic regression,  
152 among unvaccinated participants in Goma. There were too few participants who remained  
153 seronegative in Masaka and Kambia to perform this analysis there. Additionally, the  
154 distributions of log IgG MFI units to HCoVs at baseline were compared among participants  
155 who subsequently seroconverted to SARS-CoV-2 during follow up and those who remained  
156 negative during follow-up to determine if pre-existing IgG responses to endemic HCoVs  
157 predicted risk of acquisition of SARS-CoV-2 infection during the study. Log IgG MFI unit  
158 distributions were compared using the Wilcoxon rank-sum test. Linear regression of MFI  
159 units was used to determine if there was significant waning of IgG to SARS-CoV-2 RBD/NP  
160 over time, controlling for clustering of data by participant.

161 Among participants who received one or two doses of any COVID-19 vaccine before or  
162 during the study, we plotted IgG MFI to SARS-CoV-2 RBD by time since vaccination and by  
163 dose, using the recorded date of vaccination in their vaccination records. In an exploratory  
164 analysis, we looked at whether seropositivity to SARS-CoV-2 at baseline influenced

165 subsequent post-vaccination SARS-CoV-2 RBD IgG MFI, controlling for the time of sampling  
166 since vaccination.

## 167 **Results**

### 168 The study population

169 The baseline serosurvey enrolled 196 participants in February 2021 in Goma, DRC, 126  
170 participants in March 2021 in Kambia, Sierra Leone, and 250 participants in July of the same  
171 year in Masaka District, Uganda. Retention at month four was 96% in Goma (189/196), 98%  
172 in Kambia (123/126) and 92% in Masaka (230/250)(**Figure 1**). The study populations, which  
173 included everyone with patient contact at the selected health facilities, were distinct in the  
174 different settings (**Table 1**). A high proportion of Sierra Leonean staff had a mid-upper arm  
175 circumference (MUAC) of >31cm (79/126; 63%) and known pre-existing conditions (98/126;  
176 78%). At least one contact with a known COVID-19 case over the previous month was  
177 reported by 41% (103/250) of Ugandan participants, 27% (52/196) of participants in DRC but  
178 only one participant in Sierra Leone.

179 The baseline surveys were conducted just prior to the implementation of the national  
180 COVID vaccination programmes in in DRC and Sierra Leone; in both settings, vaccinations  
181 began in April 2021. In Goma, all study participants remained unvaccinated for the duration  
182 of the study; in Kambia, 49% (60/123) of participants had received at least one dose of  
183 vaccine by the end of the study (month 4). In Uganda, COVID-19 vaccination began in March  
184 2021; 14% (35/250) of study participants had been vaccinated with at least one dose at the  
185 baseline study visit in July and this increased to 56% (130/230) by the final study visit in  
186 November 2021.

187 SARS-CoV-2 seroprevalence among unvaccinated participants

188 Among unvaccinated participants, the prevalence of IgG/M to SARS-CoV-2 RBD or N-protein  
189 at enrolment was 70% (138/196) in Goma, 89% (112/126) in Kambia and 89% (190/213) in  
190 Masaka (Table 2). In Goma, 14% (28/186) of unvaccinated participants with IgG and IgM  
191 data at all timepoints, were seronegative at baseline and became seropositive during the  
192 four months of the study i.e., seroconverted; 7 (4%) sero-reverted (Suppl. Table 1). In Sierra  
193 Leone, 4 of 62 (7%) unvaccinated participants were initially seronegative and seroconverted  
194 during follow-up; 9 (15%) were initially seropositive and seroconverted during follow-up  
195 (Suppl. Table 1). In Uganda, 4 of 98 (4%) unvaccinated participants were seronegative at  
196 baseline and seroconverted during follow up and 3 of 98 (3%) unvaccinated participants  
197 were initially seropositive and seroconverted during follow-up (Suppl. Table 1). Among  
198 unvaccinated participants, almost all had detectable IgG/IgM to SARS-CoV-2 RBD/NP at least  
199 once by the end of the 4 months of follow-up: 88% were seropositive to SARS-CoV-2 at least  
200 once in Goma, 100% in Sierra Leone, and 96% in Masaka (**Table 2**, Suppl. Table 1, **Suppl Fig**  
201 **1.**).

202 Correlations between IgG responses to SARS-CoV-2 and other HCoVs

203 Across all three settings, several samples demonstrated high MFI to MERS NP, i.e.,  
204 responses at least 3 standard deviations higher than negative controls. Serum IgG bound to  
205 MERS NP, despite no known circulation of MERS or clinical presentation of the disease in  
206 these settings. Additionally, the level of binding differed by site: In Goma, 7% of samples  
207 contained IgG that bound to MERS NP, in Uganda 14% and in Sierra Leone 37% (Table 2).  
208 There were no statistically significant correlations between IgG MFI units to MERS-NP and  
209 SARS-CoV-2 NP. To determine why the prevalence of IgG binding to MERS-NP differed by

210 site we looked at correlations between IgG MFI to MERS NP protein and other HCoVs. In  
211 Goma, IgG MFI units to MERS-NP correlated with OC43-NP and 229E-NP. In Uganda, MFI to  
212 MERS-NP correlated with OC43-NP, HKU1-NP, and NL63 S1. In Sierra Leone, where MERS-NP  
213 binding was most prevalent, but the sample size was smallest, no correlations were seen  
214 between MFI units to MERS NP protein and other HCoVs (**suppl. Fig. 2, suppl. Table 2**).

215 Between 1 and 19% of samples across sites and timepoints exhibited high IgG MFI units (at  
216 least 3.s.d. higher than the MFI units in SARS-CoV-2 negative control samples) to endemic  
217 coronaviruses (Table 2). At the baseline visit, there were some correlations between MFI  
218 units of IgG to SARS-CoV-2 NP and MFI units of IgG to NP of the endemic HCoVs. In samples  
219 from Goma, MFI units of IgG to SARS-CoV-2 NP correlated with OC43-NP and 229E-NP, and  
220 IgG to SARS-CoV-2 RBD correlated with IgG to NL63 S1-protein. In samples from Uganda,  
221 MFI units of IgG to SARS-CoV-2 NP correlated with IgG MFI units to 229E-NP only. In Sierra  
222 Leone no significant correlations were detected (**Suppl. Fig. 3, Suppl. Table 3**).

223 Due to this indication of cross-binding of IgG we conducted a sensitivity analysis, excluding  
224 samples with high MFI to each HCoV in turn, and there were no significant differences in the  
225 estimates of SARS-CoV-2 seroprevalence estimated across the whole sample set and those  
226 estimated in a restricted dataset of samples with lower MFI to each HCoV (**suppl. Table 4**).

#### 227 Pre-existing HCoV IgG and 'acquisition' of SARS-CoV-2 in unvaccinated participants

228 In Goma, 28 of 186 (14%) unvaccinated participants with samples at every timepoint, were  
229 initially seronegative but seroconverted or 'acquired' SARS-CoV-2 IgG during the study; 23  
230 (12%) participants remained seronegative throughout follow-up. There were no significant  
231 differences in IgG MFI units to endemic HCoVs at baseline in participants who subsequently  
232 went on to acquire SARS-CoV-2 IgG/M compared to those who remained seronegative

233 throughout follow-up (**Fig. 2**). Too few participants remained seronegative during follow up  
234 in Sierra Leone and Uganda to contribute to this analysis.

#### 235 Rate of MFI unit decay among participants unvaccinated and seropositive at baseline

236 In an analysis of the trend in IgG MFI units over time among unvaccinated participants who  
237 were persistently seropositive, linear regression coefficients indicated MFI waning in  
238 Uganda, but not in the DRC, nor in Sierra Leone (**Figure 3**), controlling for clustering of data  
239 by participant with random effects and robust standard errors. In contrast, IgG to NP waned  
240 over time in all three settings (**Figure 3**).

#### 241 Factors associated with remaining seronegative to SARS-CoV2 among unvaccinated

242 In univariable analyses, gender was the only characteristic that was associated with  
243 remaining seronegative when compared to participants with at least one seropositive  
244 sample in Goma. Male participants had 5.9 times higher odds (95%CI 2-16) of remaining  
245 seronegative compared to female participants (**Suppl. Table 5**). In this population, there  
246 were no differences in levels of IgG to other endemic HCoVs at baseline among those who  
247 remained persistently negative and those who seroconverted (**Suppl. Fig 4**). Too few  
248 participants remained seronegative by the end of the study in Sierra Leone and Uganda to  
249 complete this analysis in those datasets.

#### 250 Serological responses to vaccination

251 In Sierra Leone, 37 of 40 (93%) participants who were vaccinated between baseline and  
252 month 2 surveys were seropositive for IgG/M to RBD/N protein by month 2, but 4 of these  
253 participants had sero-reverted by month 4. Eight of the 12 (67%) participants vaccinated  
254 between month 2 and 4 had seroconverted by month 4 (**Suppl. Table 6**). When analysing

255 IgG responses to SARS-CoV-2 RBD alone, by time since first vaccination, 19/ 78 (24%) of IgG  
256 responses to RBD were below the threshold defined as 'seropositive'. The median time since  
257 vaccination was 55 days (range 20-93 days) for these samples (**Suppl. Fig. 5**). After dose 2,  
258 11/33 participants (33%) had not mounted an IgG response to RBD that would be defined as  
259 'seropositive' in this study. These samples were taken a median of 36 days post-vaccination  
260 (range 10-76).

261 In Uganda, among participants vaccinated before the baseline survey in Uganda, all 34  
262 (100%) were still seropositive by month 4 of follow up. Among those vaccinated between  
263 the baseline and month 2 survey, 98% were seropositive by month 4 and among those  
264 vaccinated between month 2 and month 4 surveys, 88% were seropositive at month 4  
265 (**Suppl. Table 6**). When analysing IgG responses to SARS-CoV-2 RBD, by time since  
266 vaccination with the first dose, 19/128 (15%) of IgG responses to RBD were below the  
267 threshold defined as 'seropositive' – median time since vaccination was 26 days (IQR 14-87)  
268 for these samples (**Suppl. Fig. 5**).

269 None of the participants in Goma reported receiving vaccination by the end of the study.

#### 270 Prevalence of hybrid immunity and its influence on vaccine responses

271 In Sierra Leone, 70% (43/60) of the participants who were vaccinated during the study  
272 follow-up period, had evidence of natural exposure at baseline, prior to vaccination, and  
273 therefore were likely to have hybrid immunity. There was no evidence of a difference in MFI  
274 units after dose 1, comparing those participants who were seronegative at baseline with  
275 those seropositive at baseline, restricting to only samples taken at least 14 days after  
276 vaccination and controlling for the timing of sample collection since vaccination, but the  
277 sample size was small (linear reg coefficient -350; 95%CI -7388 – 6686; **Fig. 4**).

278 In Uganda, 75% (96/120) of the participants who were unvaccinated at baseline and were  
279 vaccinated during the study follow-up period, had evidence of natural exposure at baseline  
280 and are therefore likely to have hybrid immunity. There was evidence of significantly higher  
281 IgG MFI after dose 1 among those who were seropositive at baseline compared to those  
282 who were seronegative at baseline, restricting to only samples taken at least 14 days after  
283 vaccination and controlling for the timing of sample collection since vaccination (linear reg  
284 coefficient 11904, 95%CI 6233-17576; **Fig 4**).

## 285 **Discussion**

286 We documented 70-90% seroprevalence to SARS-CoV-2 in February-July 2021 among  
287 unvaccinated staff working at health facilities in three distinct settings in sub-Saharan Africa.  
288 Very few of the participants who were seronegative at the beginning of the study remained  
289 seronegative 4 months later, indicating a high force of infection. Literature indicates that  
290 SARS-CoV-2 and other HCoVs are homologous enough for their corresponding antibodies to  
291 exhibit cross-binding on ELISA/ multiplex assays[7, 9, 12] and that this cross-binding can be  
292 neutralising[24]. We found evidence that IgG to SARS-CoV-2 N-protein may cross-bind N-  
293 proteins of other endemic HCoVs and that IgG to endemic HCoVs may cross-bind MERS N-  
294 protein. It is impossible to determine whether binding IgG results from genuine prior  
295 exposure to endemic HCoVs or cross-reactivity within the assay. To attempt to control for  
296 this we conducted a sensitivity analysis of SARS-CoV-2 seroprevalence, stratified by HCoV  
297 sero-status and found no difference in our estimates of SARS-CoV-2 seroprevalence.  
298 However, numbers of participants with high MFI to endemic HCoVs in some of the  
299 comparisons are small.

300 We found evidence of waning of natural IgG to SARS-CoV-2 RBD in Uganda but not in DRC or  
301 Sierra Leone, perhaps the lack of waning was due to natural boosting with repeated re-  
302 exposure, a limitation of the study was that we did not collect swab samples for virological  
303 analyses. Cross-sectional seroprevalence estimates only provide a snapshot of a dynamic  
304 epidemic. Longitudinal follow-up documents how participants fluctuate between  
305 seropositive and seronegative status over time. Pre-existing HCoV IgG did not predict the  
306 likelihood of sero-acquisition of SARS-CoV-2 during follow-up in unvaccinated participants,  
307 perhaps because of the high force of infection in the study settings. None of the participants  
308 reported symptoms during follow-up and so we could not analyse the likelihood of  
309 symptomatic infection by HCoV serostatus at baseline. Prior studies have indicated prior  
310 exposure to HCoVs may be protective against symptomatic SARS-CoV-2[13, 14].

311 A number of participants in Sierra Leone were seronegative for IgG to RBD three or more  
312 weeks post-vaccination, this wasn't as much of a problem in Uganda. It may be that  
313 participants required more time post-vaccination to mount an IgG response to vaccination  
314 (given the observational nature of this study we had no control over when they received  
315 vaccination in relation to study visits), or IgG to RBD alone may not be a good marker of  
316 vaccination status in our settings. Three-quarters (70-75%) of those vaccinated during  
317 follow-up in Sierra Leone and Uganda had evidence of natural immunity prior to vaccination  
318 and therefore had hybrid immunity post-vaccination. Prior exposure to SARS-CoV-2  
319 correlated with better post-vaccination IgG to RBD in Uganda but not in Sierra Leone,  
320 numbers were small in this group and the analysis was limited by the lower IgG responses to  
321 vaccination in Sierra Leone. The prevalence of hybrid immunity should be built into  
322 predictions of the severity of future waves of the pandemic in these settings[2].



323 This was an observational cohort, the high SARS-CoV-2 seroprevalence at baseline and the  
324 start of the COVID-19 vaccination programme during follow up resulted in several analyses  
325 containing small numbers of participants and therefore results should be interpreted with  
326 caution. Given the number of antigens, immunoglobulins and timepoints, some of the  
327 apparent significant findings could have arisen by chance. We had no SARS-CoV-2 virological  
328 data and therefore cannot validate our definitions of ‘acquisition of infection’ with antigen  
329 data. There may be evidence of more natural boosting (re-exposure) in Sierra Leone and  
330 Goma as there was no evidence of waning of MFI units over time among seropositive  
331 participants who remained unvaccinated, however, without virological data and/or an  
332 estimate of the time of infection, it was difficult to make any conclusions here. SARS-CoV-2  
333 transmission was heterogeneous across time and geography, the findings here do not  
334 necessarily represent the overall situation among health care staff across the DRC, Uganda  
335 and Sierra Leone.

### 336 **Conclusion**

337 There was substantial transmission of SARS-CoV-2 among staff at health care facilities in  
338 Goma DRC, Masaka District, Uganda, and Kambia District, Sierra Leone over a four-month  
339 period. This will have conferred some natural immunity to infection and subsequent  
340 vaccination will confer hybrid immunity. The prevalence of natural infection could be used  
341 to inform vaccination policy, and prediction models of the impact of subsequent waves of  
342 infection in these settings.

343

### 344 **Conflict of Interest**

345 Authors declare no conflicts of interest

### 346 **Funding**

347 This project was funded by a UKRI (MRC), DHSC (NIHR) research grant (GEC1017,  
348 MR/V029363/1, PI Katherine Gallagher). The funder was not involved in study design; in the  
349 collection, analysis, and interpretation of data; in the writing of the report; and in the  
350 decision to submit the article for publication.

### 351 **Ethical Approval Statement**

352 This study was approved by the Comite National d’Ethique de la Sante (CNES) of the DRC,  
353 the Sierra Leone Ethics and Scientific Review committee, the Uganda Virus Research  
354 Institute Research Ethics Committee, the Uganda National Council for Science and  
355 Technology, the London School of Hygiene and Tropical Medicine Ethics Committee and  
356 local health authorities in each area. Written informed consent was obtained from  
357 volunteers prior to participation.

### 358 **Acknowledgements**

359 We thank the data collection teams, the health facility staff and the Ministry of Health  
360 officials in the study countries for facilitating the collection of this data. We thank Public  
361 Health England and NIBSS for supplying control samples.

362

363 REFERENCES

- 364 [1] H. N. Altarawneh *et al.*, "Effects of Previous Infection and Vaccination on Symptomatic  
365 Omicron Infections," *New England Journal of Medicine*, vol. 387, no. 1, pp. 21-34,  
366 2022/07/07 2022, doi: 10.1056/NEJMoa2203965.
- 367 [2] S. Y. Lim, S. Park, J. Y. Kim, S. Kim, Y. Jee, and S. H. Kim, "Comparison of Waning Neutralizing  
368 Antibody Responses Against the Omicron Variant 6 Months After Natural SARS-CoV-2  
369 Infection (With/Without subsequent COVID-19 Vaccination) Versus 2-dose COVID-19  
370 Vaccination," (in eng), *Clinical infectious diseases : an official publication of the Infectious  
371 Diseases Society of America*, Jun 10 2022, doi: 10.1093/cid/ciac435.
- 372 [3] Africa CDC. "COVID-19 Vaccine Dashboard Latest updates from Africa CDC on progress made  
373 in COVID-19 vaccinations on the continent." <https://africacdc.org/covid-19-vaccination/>  
374 (accessed 10 September 2022).
- 375 [4] J. S. Kahn and K. McIntosh, "History and Recent Advances in Coronavirus Discovery," *The  
376 Pediatric Infectious Disease Journal*, vol. 24, no. 11, pp. S223-S227, 2005, doi:  
377 10.1097/01.inf.0000188166.17324.60.
- 378 [5] L. Santacroce, I. A. Charitos, D. M. Carretta, E. De Nitto, and R. Lovero, "The human  
379 coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection," (in eng), *J  
380 Mol Med (Berl)*, vol. 99, no. 1, pp. 93-106, Jan 2021, doi: 10.1007/s00109-020-02012-8.
- 381 [6] Center for Diseases Control and Prevention (CDC). "Common Human Coronaviruses."  
382 National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral  
383 Diseases. [https://www.cdc.gov/coronavirus/general-  
384 information.html#:~:text=Common%20human%20coronaviruses%2C%20including%20types,  
385 some%20point%20in%20their%20lives.](https://www.cdc.gov/coronavirus/general-information.html#:~:text=Common%20human%20coronaviruses%2C%20including%20types,some%20point%20in%20their%20lives.) (accessed 11 September 2022, 2022).
- 386 [7] K. Shrwani *et al.*, "Detection of Serum Cross-Reactive Antibodies and Memory Response to  
387 SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples," (in eng), *J Infect Dis*,  
388 vol. 224, no. 8, pp. 1305-1315, Oct 28 2021, doi: 10.1093/infdis/jiab333.
- 389 [8] K. W. Ng *et al.*, "Preexisting and de novo humoral immunity to SARS-CoV-2 in humans," (in  
390 eng), *Science (New York, N.Y.)*, vol. 370, no. 6522, pp. 1339-1343, Dec 11 2020, doi:  
391 10.1126/science.abe1107.
- 392 [9] L. Guo *et al.*, "Cross-reactive antibody against human coronavirus OC43 spike protein  
393 correlates with disease severity in COVID-19 patients: a retrospective study," (in eng), *Emerg  
394 Microbes Infect*, vol. 10, no. 1, pp. 664-676, Dec 2021, doi:  
395 10.1080/22221751.2021.1905488.
- 396 [10] A. T. Huang *et al.*, "A systematic review of antibody mediated immunity to coronaviruses:  
397 kinetics, correlates of protection, and association with severity," (in eng), *Nat Commun*, vol.  
398 11, no. 1, p. 4704, Sep 17 2020, doi: 10.1038/s41467-020-18450-4.
- 399 [11] J. Wang *et al.*, "Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk  
400 Induced by COVID-19 Vaccination and Infection," (in eng), *Vaccines*, vol. 10, no. 6, Jun 20  
401 2022, doi: 10.3390/vaccines10060980.
- 402 [12] J. Wang *et al.*, "IgG Against Human  $\beta$ -Coronavirus Spike Proteins Correlates with SARS-CoV-2  
403 anti-Spike IgG Responses and COVID-19 Disease Severity," (in eng), *J Infect Dis*, Jan 29 2022,  
404 doi: 10.1093/infdis/jiac022.
- 405 [13] M. Sagar *et al.*, "Recent endemic coronavirus infection is associated with less-severe COVID-  
406 19," (in eng), *J Clin Invest*, vol. 131, no. 1, Jan 4 2021, doi: 10.1172/jci143380.
- 407 [14] N. Ortega *et al.*, "Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing  
408 antibodies to human coronaviruses," (in eng), *Nat Commun*, vol. 12, no. 1, p. 4740, Aug 6  
409 2021, doi: 10.1038/s41467-021-24979-9.
- 410 [15] WHO Regional Office for Africa. "Sierra Leone confirms first case of COVID-19."  
411 <https://www.afro.who.int/news/sierra-leone-confirms-first-case-covid-19> (accessed 22 June  
412 2022).

- 413 [16] WHO Regional Office for Africa. "First case of COVID-19 confirmed in the Democratic  
414 Republic of the Congo." [https://www.afro.who.int/news/first-case-covid-19-confirmed-](https://www.afro.who.int/news/first-case-covid-19-confirmed-democratic-republic-congo)  
415 [democratic-republic-congo](https://www.afro.who.int/news/first-case-covid-19-confirmed-democratic-republic-congo) (accessed 22 June 2022).
- 416 [17] R. Olum and F. Bongomin, "Uganda's first 100 COVID-19 cases: Trends and lessons," (in eng),  
417 *Int J Infect Dis*, vol. 96, pp. 517-518, 2020, doi: 10.1016/j.ijid.2020.05.073.
- 418 [18] WHO Regional Office for Africa. "Nearly 20% of target population vaccinated as Sierra Leone  
419 marks one year of COVID-19 vaccine launch." [https://www.afro.who.int/countries/sierra-](https://www.afro.who.int/countries/sierra-leone/news/nearly-20-target-population-vaccinated-sierra-leone-marks-one-year-covid-19-vaccine-launch)  
420 [leone/news/nearly-20-target-population-vaccinated-sierra-leone-marks-one-year-covid-19-](https://www.afro.who.int/countries/sierra-leone/news/nearly-20-target-population-vaccinated-sierra-leone-marks-one-year-covid-19-vaccine-launch)  
421 [vaccine-launch](https://www.afro.who.int/countries/sierra-leone/news/nearly-20-target-population-vaccinated-sierra-leone-marks-one-year-covid-19-vaccine-launch) (accessed 22/06/2022).
- 422 [19] Health Policy Watch. "DRC Finally Launches COVID-19 Vaccinations After Investigating  
423 Concerns About AstraZeneca." [https://healthpolicy-watch.news/dr-congo-finally-launches-](https://healthpolicy-watch.news/dr-congo-finally-launches-covid-19-vaccinations-after-concerns-about-astrazeneca/)  
424 [covid-19-vaccinations-after-concerns-about-astrazeneca/](https://healthpolicy-watch.news/dr-congo-finally-launches-covid-19-vaccinations-after-concerns-about-astrazeneca/) (accessed 26 June 2022).
- 425 [20] Unicef Uganda. "Uganda launches first phase of COVID-19 vaccination exercise."  
426 [https://www.unicef.org/uganda/stories/uganda-launches-first-phase-covid-19-vaccination-](https://www.unicef.org/uganda/stories/uganda-launches-first-phase-covid-19-vaccination-exercise)  
427 [exercise](https://www.unicef.org/uganda/stories/uganda-launches-first-phase-covid-19-vaccination-exercise) (accessed 22/06/ 2022, 22/06/ 2022).
- 428 [21] WHO Regional Office for Africa. "Africa's COVID-19 vaccine uptake increases by 15%."  
429 [https://www.afro.who.int/news/africas-covid-19-vaccine-uptake-increases-](https://www.afro.who.int/news/africas-covid-19-vaccine-uptake-increases-15#:~:text=Brazzaville%20%E2%80%93%20Africa's%20COVID%2D19%20vaccine,health%20i)  
430 [15#:~:text=Brazzaville%20%E2%80%93%20Africa's%20COVID%2D19%20vaccine,health%20i](https://www.afro.who.int/news/africas-covid-19-vaccine-uptake-increases-15#:~:text=Brazzaville%20%E2%80%93%20Africa's%20COVID%2D19%20vaccine,health%20i)  
431 [mpacts%20of%20the%20virus.](https://www.afro.who.int/news/africas-covid-19-vaccine-uptake-increases-15#:~:text=Brazzaville%20%E2%80%93%20Africa's%20COVID%2D19%20vaccine,health%20i) (accessed 26/06/2022).
- 432 [22] L. Wu *et al.*, "Optimisation and standardisation of a multiplex immunoassay of diverse  
433 *Plasmodium falciparum* antigens to assess changes in malaria transmission using sero-  
434 epidemiology," (in eng), *Wellcome Open Res*, vol. 4, p. 26, 2019, doi:  
435 10.12688/wellcomeopenres.14950.2.
- 436 [23] S. Park, Y. Lee, I. C. Michelow, and Y. J. Choe, "Global Seasonality of Human Coronaviruses: A  
437 Systematic Review," (in eng), *Open Forum Infect Dis*, vol. 7, no. 11, pp. ofaa443-ofaa443,  
438 2020, doi: 10.1093/ofid/ofaa443.
- 439 [24] J. Nyagwange *et al.*, "Serum immunoglobulin G and mucosal immunoglobulin A antibodies  
440 from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro," (in  
441 eng), *Int J Infect Dis*, vol. 127, pp. 11-16, Feb 2023, doi: 10.1016/j.ijid.2022.11.041.

442

COVID19 HWI serosurvey manuscript - Tables

**Table 1. Description of the study population**

Participant characteristics	Goma DRC		Kambia Sierra Leone		Masaka Uganda	
	N	%	N	%	N	%
<b>Total enrolled<sup>1</sup></b>	196		126		250	
<b>Total at final study visit (month 4)</b>	189	96.4	123	97.6	230	92.0
Age (median, range)	39	(15-76)	38	(20-68)	35	(18-74)
Female	111	56.6	81	64.3	171	68.4
<b>Role in the facility<sup>2</sup></b>						
Doctor or clinical officer	4	2.0	0	0	17	6.8
Nurse or midwife <sup>3</sup>	159	81.1	29	23.0	103	41.2
Clinical support staff <sup>4</sup>	13	6.6	70	55.6	70	28.0
Laboratory/ pharmacy staff <sup>5</sup>	18	9.2	13	10.3	35	14.0
Non-clinical support staff <sup>6</sup>	2	1.0	14	11.1	25	10.0
<b>Highest level of schooling</b>						
None <sup>7</sup>	1	0.5	7	5.6	1	0.4
Complete primary	1	0.5	1	0.8	7	2.8
Incomplete secondary	15	7.7	31	24.6	21	8.4
Complete secondary & above	178	90.8	86	68.3	221	88.4
<b>Smoker (once per week or more)</b>						
Yes	0	0	14	11.1	2	0.8
No	195	100	112	88.9	248	99.2
<b>Mid-Upper Arm Circumference (MUAC)</b>						
<24cm	17	8.7	2	1.6	11	4.4
24-31cm	139	70.9	45	35.7	163	65.2
>31cm	40	20.4	79	62.7	76	30.4
<b>Known contact with a confirmed COVID-19 case</b>						
Yes	52	26.5	1	0.8	103	41.2
No	144	73.5	125	99.2	147	58.8
<b>No. People sharing the participant's room to sleep</b>						
0 people	126	64.3	44	34.9	208	83.2
1-2 people	56	28.6	18	14.3	26	10.4
3 people	11	5.6	25	19.8	10	4.0
>=4 people	3	1.5	39	31.0	6	2.4
<b>Use of a mask at work</b>						
None of the time	0	0	0	0	0	0
Half the time	33	16.8	4	3.2	10	4.0
Most but not all of the time	99	50.5	70	55.6	51	20.4
All the time	64	32.7	50	39.7	189	75.6
Don't know	0	0	2	1.6	0	0
<b>Reported COVID-19 symptoms in the last month<sup>8</sup></b>						
Yes	75	38.3	16	12.7	116	46.4
No	121	61.7	110	87.3	134	53.6
<b>Known pre-existing conditions<sup>9</sup></b>						
Yes	37	18.9	98	77.8	65	26.0
No	159	81.1	28	22.2	185	74.0
<b>COVID-19 vaccination status at baseline (<math>\geq 1</math> dose)<sup>10</sup></b>						
Yes	0	0	0	0	35	14.0
No	196	100	126	100	215	86.0
<b>COVID-19 vaccination status at M2 (<math>\geq 1</math>)</b>						

COVID19 HWI serosurvey manuscript - Tables

dose) <sup>10</sup>	Yes	0	0	48	39.0	89	38.7
	No	189	100	75	61.0	141	61.3
<b>COVID-19 vaccination status at M4 (at least one dose)<sup>10</sup></b>	Yes	0	0	60	48.8	130	56.5
	No	189	100	63	51.2	100	43.5
<b>Immunisation record among those vaccinated at any timepoint</b>	Verbal	0	0	0	0	69	53.1
	Written	0	0	60	100	14	10.8
<b>Vaccine product (Dose 1)<sup>11</sup></b>	AstraZeneca	0	0	29	48.3	14	100
	SinoPharm	0	0	31	51.7	0	0

<sup>1</sup> The baseline serosurvey was conducted in February 2021 in Goma, DRC, in March 2021 in Kambia, Sierra Leone and in July 2021 in Masaka district, Uganda. Percentages are column percentages.

<sup>2</sup> All categories include trainees.

<sup>3</sup> Includes registered, enrolled or assistant nurses and midwives, and community health nurses.

<sup>4</sup> Includes health attendants and assistants, maternal and child health aids, antenatal care workers, community health workers, counsellors, peer/health educators, nutritionists, physiotherapists, psychologists, social workers and triage/screening staff.

<sup>5</sup> Includes laboratory technicians and assistants, and pharmacists and pharmacy attendants.

<sup>6</sup> Includes community linkage personnel, ambulance drivers, data clerks, health information assistants, health inspectors, porters, receptionists, retention officers and other support staff incl. traditional birth attendants.

<sup>7</sup> All participants who reported no education or incomplete primary school education were acting as non-clinical support staff or assistants. e.g. In Kambia: 1 was a traditional birth attendant, 2 were laboratory assistants, 1 was a porter and 1 had a role in participant screening.

<sup>8</sup> Symptoms included: History of fever/ chills, shortness of breath, aches/pain, general weakness/ malaise, diarrhoea, cough, nausea/vomiting, sore throat, headache, runny nose, irritability/confusion, loss of sense of smell or taste.

<sup>9</sup> Pre-existing conditions included known 'diagnoses' of: Pregnancy, obesity, cancer, diabetes, HIV/other immune deficiency, heart disease, asthma (requiring medication), chronic lung disease (non-asthma), chronic liver disease, chronic haematological disorder, chronic kidney disease, chronic neurological impairment/disease, organ or bone marrow recipient.

<sup>10</sup> Vaccination status is as recorded at the visit from immunisation records or participant recall, no vaccines were delivered at study visits or as part of the study.

<sup>11</sup> Vaccine product was only recorded among participants with a written immunisation record. There was no recorded mixing of products among those who were vaccinated with >1 dose.

COVID19 HWI serosurvey manuscript - Tables

**Table 2. SARS-CoV-2 seroprevalence among unvaccinated participants<sup>1</sup> and the prevalence of samples with high MFI to other HCoVs**

<b>Goma, DRC</b>	<b>D0 (Feb 2021)</b>			<b>M2 (April 2021)</b>			<b>M4 (June 2021)</b>		
	N	n (pos)	%	N	n (pos)	%	N	n (pos)	%
SARS2 RBD IgG	196	98	50	189	116	61.4	189	119	63
SARS2 NP IgG	196	110	43.9	189	121	64	189	116	61.4
SARS2 RBD/NP IgG	196	125	63.8	189	145	76.7	189	146	77.3
SARS2 RBD/NP IgG/IgM	196	138	70.4	189	152	80.4	189	157	83.1
MERS NP IgG	196	14	7.1	188	13	6.9	189	12	6.3
OC43 NP IgG	196	5	2.6	189	1	0.5	189	7	3.7
229E NP IgG	196	5	2.6	188	3	1.6	189	9	4.8
HKU1 NP IgG	196	22	11.2	189	13	6.9	189	22	11.6
NL63 S1 IgG	196	9	4.6	189	4	2.1	189	6	3.2

<b>Kambia, Sierra Leone</b>	<b>D0 (March 2021)</b>			<b>M2 (May 2021)</b>			<b>M4 (July 2021)</b>		
	N	n (pos)	%	N	n (pos)	%	N	n (pos)	%
SARS2 RBD IgG	126	70	55.6	75	51	68.0	62	34	54.8
SARS2 NP IgG	126	90	71.4	75	53	70.7	62	36	58.1
SARS2 RBD/NP IgG	126	98	77.8	75	59	78.7	62	43	69.4
SARS2 RBD/NP IgG/IgM	126	112	88.9	75	66	88	62	51	73.3
MERS NP IgG	126	46	36.5	75	21	28.0	62	14	22.6
OC43 NP IgG	126	24	19.1	75	10	13.3	62	4	6.5
229E NP IgG	126	4	3.2	75	1	1.3	62	1	1.6
HKU1 NP IgG	126	29	23.0	75	19	25.3	62	12	19.4
NL63 S1 IgG	126	10	7.9	75	8	10.7	62	4	6.5

<b>Masaka, Uganda</b>	<b>D0 (July 2021)</b>			<b>M2 (Sept 2021)</b>			<b>M4 (Nov 2021)</b>		
	N	n (pos)	%	N	n (pos)	%	N	n (pos)	%
SARS2 RBD IgG	213	157	73.7	141	105	74.5	98	81	82.7
SARS2 NP IgG	213	135	63.4	141	86	61.0	98	61	62.2
SARS2 RBD/NP IgG	213	172	80.8	141	118	83.7	98	86	87.8
SARS2 RBD/NP IgG/M	213	190	89.2	141	118	83.7	98	91	92.9
MERS NP IgG	213	31	14.6	141	15	10.6	98	10	10.2


## COVID19 HWI serosurvey manuscript - Tables

OC43 NP IgG	213	10	4.7	141	5	3.5	98	5	5.1
L229E NP IgG	213	16	7.5	141	2	1.4	98	1	1.0
HKU1 NP IgG	213	27	12.7	141	13	9.2	98	15	15.3
LNL63 S1 IgG	213	28	13.1	141	16	11.3	98	8	8.2

<sup>1</sup> SARS-CoV-2 seropositivity was defined as MFI units more than 3.s.d from the mean of EU negative controls. HCoV seropositivity is also defined as 3.s.d. from the mean of EU control samples; however, true negatives were not possible to define due to the endemic nature of HCoVs globally therefore seropositivity is defined here qualitatively and should be interpreted as indicative of high MFI units rather than a classification of prior exposure or protective titres. In DRC all participants were unvaccinated for the duration of the study, participants who were vaccinated in Sierra Leone and Uganda are not included in this table.




**Figure 1. Study timeline and participant flow<sup>1</sup>**




<sup>1</sup>COVID-19 vaccination programmes started in Sierra Leone and Uganda in March 2021, and in DRC in April 2021

**Figure 1. HCoV IgG MFI units at baseline, comparing 23 participants who remained seronegative during follow up with 28 participants who were seronegative at baseline and acquired SARS-CoV-2 infection during follow up (seroconverted to SARS-CoV-2 RBD/NP IgG/M at Month 2 or 4), in Goma. P-values are for a Wilcoxon rank-sum test**




**Fig 2. Trends in IgG MFI units to SARS-CoV-2 RBD and NP over time, among those persistently positive for IgG or IgM to RBD or NP<sup>1</sup>**

<sup>1</sup> Spaghetti plots represent the predicted linear trends for each participant in light blue lines, and the bold line indicates the average slope across participants. The actual linear regression coefficient (slope), controlling for clustering of data by participant with random effects and robust standard errors, is indicated below each graph with its 95%CI. The number of participants included are as follows: DRC n=119; Sierra Leone n=41; Uganda n=83.



**Fig 3. IgG to SARS-CoV-2 RBD >14 days post-vaccination with 1 dose, by serostatus at baseline. P-values from the Wilcoxon Rank Sum test.**



<sup>1</sup> In Sierra Leone just 5 seronegative participants at baseline (i.e. seronegative for IgM and IgG to RBD and NP) had a recorded vaccination date and a blood sample >14 days after vaccination (Sero(-) group n=4), 44 participants were seropositive at baseline (i.e. were seropositive for IgM or IgG to RBD or NP) had a recorded vaccination date and a blood sample >14 days after vaccination (Sero(+) group n=44); median of 47 days between vaccination and a study sample (IQR 28-56, range 15-79).

<sup>2</sup> In Uganda, just 12 unvaccinated and seronegative participants at baseline had a recorded vaccination date after baseline and a blood sample >14 days after vaccination, 96 participants were seropositive at baseline and had a recorded vaccination date after baseline, with a blood sample >14 days after vaccination. Median interval between vaccination and blood sample was 42 days (IQR 28-88).